Décard B - Search Results

1

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.

von Wyl V, Benkert P, Moser A, Lorscheider J, Décard B, Hänni P, Lienert C, Kuhle J, Derfuss T, Kappos L, Yaldizli Ö. von Wyl V, et al. Among authors: decard b. Mult Scler. 2021 Mar;27(3):439-448. doi: 10.1177/1352458520918489. Epub 2020 May 28. Mult Scler. 2021. PMID: 32463336

2

Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.

Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R. Décard BF, et al. Mult Scler. 2013 Feb;19(2):249-51. doi: 10.1177/1352458512448268. Epub 2012 May 17. Mult Scler. 2013. PMID: 22596228

3

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.

Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL. Meira M, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27088119 Free PMC article.

4

Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.

Décard BF, Derfuss T. Décard BF, et al. Semin Neurol. 2016 Apr;36(2):128-39. doi: 10.1055/s-0036-1580720. Epub 2016 Apr 26. Semin Neurol. 2016. PMID: 27116719 Review.

5

Extensive bilateral brain lesions in neuromyelitis optica spectrum disorders.

Décard BF, Derfuss T. Décard BF, et al. Mult Scler. 2018 Aug;24(9):1262-1263. doi: 10.1177/1352458518771888. Epub 2018 Apr 20. Mult Scler. 2018. PMID: 29676200 No abstract available.

6

A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.

Diebold M, Müller S, Derfuss T, Décard BF. Diebold M, et al. Mult Scler Relat Disord. 2019 Jun;31:38-40. doi: 10.1016/j.msard.2019.03.009. Epub 2019 Mar 9. Mult Scler Relat Disord. 2019. PMID: 30901703

7

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J. Diebold M, et al. Mult Scler. 2019 Oct;25(12):1682-1685. doi: 10.1177/1352458519852100. Epub 2019 Jun 18. Mult Scler. 2019. PMID: 31208265

8

PML with dimethyl fumarate-No convincing case against natalizumab.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J. Diebold M, et al. Mult Scler. 2019 Oct;25(12):1687-1688. doi: 10.1177/1352458519872894. Epub 2019 Aug 22. Mult Scler. 2019. PMID: 31436113 No abstract available.

9

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.

Diebold M, Fischer-Barnicol B, Tsagkas C, Kuhle J, Kappos L, Derfuss T, Décard BF. Diebold M, et al. Among authors: decard bf. Neurol Neuroimmunol Neuroinflamm. 2019 Jul 11;6(5):e594. doi: 10.1212/NXI.0000000000000594. Print 2019 Sep. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31454772 Free PMC article.

10

New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.

Sinnecker T, Ruberte E, Schädelin S, Canova V, Amann M, Naegelin Y, Penner IK, Müller J, Kuhle J, Décard B, Derfuss T, Kappos L, Granziera C, Wuerfel J, Magon S, Yaldizli Ö. Sinnecker T, et al. Among authors: decard b. J Neurol. 2020 Jan;267(1):192-202. doi: 10.1007/s00415-019-09565-w. Epub 2019 Oct 14. J Neurol. 2020. PMID: 31612322

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page